View the latest news and SEC filings
Scroll to
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
August 5, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 5, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
July 29, 2024 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
July 12, 2024 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
June 27, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
May 10, 2024 |
Quarterly report which provides a continuing view of a company’s financial position |
10-Q |
Quarterly Filings |
|
|
May 10, 2024 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
May 9, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
May 9, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
